The use of SGLT2 inhibitors and GLP analogues however, is still in transition as clinical studies point to broadened indications (e.g. nephropathy and overweight management) and future studies are warranted to explore how this may affect gender differences in GLD initiation. This evidence concerns the gene SLC5A2 and kidney disorder.